Melegh B, Pap M, Bock I, Rebouche C J
Department of Pediatrics, University Medical School of Pécs, Hungary.
Pediatr Res. 1993 Oct;34(4):460-4. doi: 10.1203/00006450-199310000-00015.
Plasma concentrations and rates of urinary excretion of carnitine and some of its precursors were studied in three groups of children receiving drugs known to cause carnitine depletion. Patients in group A received pivampicillin and a molar equivalent of carnitine for 7 d. Patients in group B received pivampicillin with a 5.8-fold molar excess of carnitine for 1 wk. Patients in group C were treated chronically with valproic acid and received a molar equivalent (to valproic acid) of carnitine for 14 d. Patients in group A had markedly increased (16-fold) urinary carnitine ester excretion concomitant with diminished urinary free carnitine and gamma-butyrobetaine output and lower plasma free carnitine concentration. Supplementation with one molar equivalent of carnitine (to pivampicillin) was ineffective in preventing the reduction of plasma carnitine concentration observed with pivampicillin treatment alone. For group B patients, administration of excess carnitine resulted in a further increase (35-fold) of urinary carnitine ester output with no decrease of plasma carnitine concentration, urinary gamma-butyrobetaine, or free carnitine excretion. For patients in group C, the initially low plasma free and total carnitine concentrations and urinary output of carnitine and carnitine esters markedly increased with carnitine supplementation, but urinary excretion of gamma-butyrobetaine remained unchanged. The plasma concentrations and urinary output of L-lysine and epsilon-N-trimethyllysine remained unchanged within each group before and after treatment. A positive linear correlation was found between urinary epsilon-N-trimethyllysine and 3-methylhistidine output, indicating that the rate of epsilon-N-trimethyllysine excretion correlates with the amount of 3-methylhistidine liberated by protein turnover.(ABSTRACT TRUNCATED AT 250 WORDS)
在三组接受已知会导致肉碱缺乏药物治疗的儿童中,研究了肉碱及其一些前体的血浆浓度和尿排泄率。A组患者接受匹氨西林和等摩尔当量的肉碱治疗7天。B组患者接受匹氨西林和5.8倍摩尔过量的肉碱治疗1周。C组患者长期接受丙戊酸治疗,并接受与丙戊酸等摩尔当量的肉碱治疗14天。A组患者尿肉碱酯排泄显著增加(16倍),同时尿游离肉碱和γ-丁甜菜碱排出量减少,血浆游离肉碱浓度降低。补充与匹氨西林等摩尔当量的肉碱(相对于匹氨西林),对于预防单独使用匹氨西林治疗时观察到的血浆肉碱浓度降低无效。对于B组患者,给予过量肉碱导致尿肉碱酯排出量进一步增加(35倍),而血浆肉碱浓度、尿γ-丁甜菜碱或游离肉碱排泄均未降低。对于C组患者,补充肉碱后,最初较低的血浆游离和总肉碱浓度以及肉碱和肉碱酯的尿排出量显著增加,但γ-丁甜菜碱的尿排泄量保持不变。每组治疗前后L-赖氨酸和ε-N-三甲基赖氨酸的血浆浓度和尿排出量均保持不变。尿ε-N-三甲基赖氨酸和3-甲基组氨酸排出量之间呈正线性相关,表明ε-N-三甲基赖氨酸的排泄率与蛋白质周转释放的3-甲基组氨酸量相关。(摘要截短于250字)